Direkt zum Inhalt

Fröhlich, Holger ; Balling, R. ; Beerenwinkel, N. ; Kohlbacher, O. ; Kumar, S. ; Lengauer, T. ; Maathuis, M. H. ; Moreau, Y. ; Murphy, S. A. ; Przytycka, T. M. ; Rebhan, M. ; Rost, H. ; Schuppert, A. ; Schwab, M. ; Spang, Rainer ; Stekhoven, D. ; Sun, J. ; Weber, A. ; Ziemek, D. ; Zupan, B.

From hype to reality: data science enabling personalized medicine

Fröhlich, Holger, Balling, R. , Beerenwinkel, N., Kohlbacher, O., Kumar, S., Lengauer, T., Maathuis, M. H., Moreau, Y., Murphy, S. A., Przytycka, T. M. , Rebhan, M., Rost, H. , Schuppert, A. , Schwab, M., Spang, Rainer, Stekhoven, D., Sun, J., Weber, A., Ziemek, D. and Zupan, B. (2018) From hype to reality: data science enabling personalized medicine. BMC Med 16 (1), p. 150.

Date of publication of this fulltext: 11 Sep 2018 08:17
Article
DOI to cite this document: 10.5283/epub.37702


Abstract

Background: Personalized, precision, P4, or stratified medicine is understood as a medical approach in which patients are stratified based on their disease subtype, risk, prognosis, or treatment response using specialized diagnostic tests. The key idea is to base medical decisions on individual patient characteristics, including molecular and behavioral biomarkers, rather than on population ...

Background: Personalized, precision, P4, or stratified medicine is understood as a medical approach in which patients are stratified based on their disease subtype, risk, prognosis, or treatment response using specialized diagnostic tests. The key idea is to base medical decisions on individual patient characteristics, including molecular and behavioral biomarkers, rather than on population averages. Personalized medicine is deeply connected to and dependent on data science, specifically machine learning (often named Artificial Intelligence in the mainstream media). While during recent years there has been a lot of enthusiasm about the potential of 'big data' and machine learning-based solutions, there exist only few examples that impact current clinical practice. The lack of impact on clinical practice can largely be attributed to insufficient performance of predictive models, difficulties to interpret complex model predictions, and lack of validation via prospective clinical trials that demonstrate a clear benefit compared to the standard of care. In this paper, we review the potential of state-of-the-art data science approaches for personalized medicine, discuss open challenges, and highlight directions that may help to overcome them in the future. Conclusions: There is a need for an interdisciplinary effort, including data scientists, physicians, patient advocates, regulatory agencies, and health insurance organizations. Partially unrealistic expectations and concerns about data science-based solutions need to be better managed. In parallel, computational methods must advance more to provide direct benefit to clinical practice.



Involved Institutions


Details

Item typeArticle
Journal or Publication TitleBMC Med
Publisher:BMC
Place of Publication:LONDON
Volume:16
Number of Issue or Book Chapter:1
Page Range:p. 150
Date27 August 2018
InstitutionsMedicine > Institut für Funktionelle Genomik > Lehrstuhl für Statistische Bioinformatik (Prof. Spang)
Informatics and Data Science > Department Computational Life Science > Lehrstuhl für Statistische Bioinformatik (Prof. Spang)
Identification Number
ValueType
10.1186/s12916-018-1122-7DOI
30145981PubMed ID
KeywordsBIG DATA; BREAST-CANCER; HYBRID MODELS; HEALTH; CAUSAL; PREDICTION; SIGNATURE; PATIENT; EVOLUTION; DISCOVERY; Personalized medicine; Precision medicine; Stratified medicine; P4 medicine; Machine learning; Artificial intelligence; Big data; Biomarkers
Dewey Decimal Classification600 Technology > 610 Medical sciences Medicine
StatusPublished
RefereedYes, this version has been refereed
Created at the University of RegensburgPartially
URN of the UB Regensburgurn:nbn:de:bvb:355-epub-377029
Item ID37702

Export bibliographical data

Owner only: item control page

nach oben